Syntara Limited · ASX:SNT
Syntara — NWR Virtual Healthcare Conference (March 2024)
19 slides from Syntara's conference presentation, Mar 20, 2024
Slide 1: NWR Virtual Healthcare Conference
™ NWR Virtual Healthcare Conference Gary Phillips, CEO 20th March 2024
Slide 2: Forward looking statement
Forward looking statement This document contains involve known and unknown forward-looking statements, risks, uncertainties and other including statements factors, many of which are concerning Syntara’s future beyond our control, and which financial position, plans, and may cause actual results to t
Slide 3: Global leaders in lysyl oxidase enzymes; prioritising Myelofibrosis
Global leaders in lysyl oxidase Prioritising Myelofibrosis (MF) • Market opportunities in excess of US$1b per enzymes with three Nature annum and recent history of biotech exits in publications and a pipeline of clinical excess of US$1.7b stage drugs in fibrosis and • SNT-5505 Monotherapy study repo
Slide 4: Shareholders & cash
Shareholders & cash Financial Information (ASX: SNT) 14 Mar 24 Share Price & Volume Share price $0.020 0.07 Market Cap A$24m Proforma cash balance (31 December 0.06 A$13m 2023)1 0.05 Enterprise value A$11m Note: 0.04 1. Proforma cash: Cash $6m plus $7m proceeds of placement second tranche 0.03 2. Cl
Slide 5: Syntara Board under new leadership and downsized
Syntara Board under new leadership and downsized Significant international pharmaceutical experience Dr Kathleen Metters Dr Simon Green Gary Phillips Hashan De Silva Chair Non-Executive Director Chief Executive Officer Non-Executive Director • Former Senior Vice President • Experienced senior global
Slide 6: Syntara is the global leader in lysyl oxidase chemistry and biology
Syntara is the global leader in lysyl oxidase chemistry and biology Multi year research program leveraged with extensive scientific collaborations worldwide has delivered 3 drugs now in phase 1c/2 studies Lysyl oxidases mediate the final stage in fibrosis SNT-5505 in Oncology Topical pan-LOX inhibit
Slide 7: Preclinical science and collaborations validated in high impact publications
Preclinical science and collaborations validated in high impact publications Myelofibrosis Myelodysplastic • Treatment with Syndrome lysyl oxidase • In xenograft inhibitor mouse model that significantly closely resembles reduced reticulin human disease, fibrosis and SNT-5505 on top of megakaryocyte
Slide 8: Myelofibrosis (MF)
®&|SYNTARA Myelofibrosis (MF)
Slide 9: Myelofibrosis
Myelofibrosis A rare type of bone marrow cancer that disrupts the body's normal production of blood cells Key Facts Primary Myelofibrosis is Current standard SNT-5505 characterised by a build up of scar of care (SoC): JAK inhibition In contrast to SoC tissue (fibrosis) in bone marrow SNT-5505 interv
Slide 10: SNT-5505 Phase 2a trial (INTERIM results)
SNT-5505 Phase 2a trial (INTERIM results) Study status Efficacy • 100% of target (24 pts) enrolled • 5/ 10 evaluable patients* had improved bone • 11 patients having completed 24 marrow fibrosis scores of ≥1 grade weeks of treatment - 4 out of 5 fibrosis responders demonstrating stable/improved haem
Slide 11: Myelodysplastic Syndromes (MDS)
Myelodysplastic Syndromes (MDS)
Slide 12: Myelodysplastic syndrome (MDS) is a blood cancer
Myelodysplastic syndrome (MDS) is a blood cancer Diverse bone marrow disorders characterized by inadequate production of healthy blood cells Key Facts 12–20k new cases are reported every Treatment of MDS year in the US (87k p.a. worldwide) Current standard of care Drugs in development SNT-5505; pote
Slide 13: Phase 1c/2a study; SNT-5505 in MDS patients
Phase 1c/2a study; SNT-5505 in MDS patients Study organisation Fastest route to meaningful data with no dose escalation and utilizing existing trial infrastructure • $0.83m grant from the Australian Medical Research Future Study Treatment Fund (MRFF). Patients Design Endpoints Population Cohort • In
Slide 14: Skin Scarring
Skin Scarring
Slide 15: Hypertrophic and keloid scarring
Hypertrophic and keloid scarring Cutaneous scarring following skin trauma or a wound is a major cause of morbidity and disfigurement Key Facts • Mechanisms underlying scar • Pre clinical evidence formation are not well established; prophylactic and - Treatment with SNT-6302 100m patients develop sca
Slide 16: SNT-6302 Phase 1c Trial in established skin scars; top line results
SNT-6302 Phase 1c Trial in established skin scars (Solaria 2); Top line results SNT-6302 well tolerated Mean inhibition of LOX Meaningful changes in the Longer study required to and demonstrated a activity 66% compared to composition of the scars show appearance and good safety profile. baseline and
Slide 17: Potential to deliver near term value
Potential to deliver near term value Pipeline creates multiple opportunities in high value markets Addressable market Drug Candidate Indication Phase Upcoming Milestones (US$) Interim 6 month data Myelofibrosis (MF) Phase 2 ~$1 billion1 Q4 2024 SNT-5505 Myelodysplastic Syndrome Phase 1c/2 Data H1 20
Slide 18: Recent & upcoming news flow
Recent & upcoming news flow Strong and growing pipeline with advancement in studies expected to provide value inflection points Q4 2023 H1 2024 H2 2024 • SNT-5505 phase 2a myelofibrosis • Pan-LOX scar prevention for burn • SNT-5505 phase 1c/2a combination study (add on to JAK injuries- clinical tria
Slide 19: Gary Phillips contact details
Gary Phillips Syntara Limited ABN 75 082 811 630 Chief Executive Officer gary.phillips@syntaraTX.com.au David McGarvey Chief Financial Officer david.mcgarvey@syntaraTX.com.au www.syntaraTX.com.au
Syntara — NWR Virtual Healthcare Conference (March 2024) on 6ix